Peptron is showing strong performance. It appears that the stock price is being influenced by expectations that the company will accelerate technology exports of obesity and diabetes treatments.
As of 9:49 AM on the 28th, Peptron is trading at 28,800 KRW, up 7.06% from the previous day.
On this day, a media outlet reported that the Ministry of Food and Drug Safety visited Peptron's Osong plant in Chungbuk to conduct an on-site inspection for the production of ‘Loopone,’ a 1-month sustained-release formulation of leuprorelin for prostate cancer and precocious puberty treatment.
Industry insiders expect Loopone to be a ‘game changer’ in the domestic and international 1-month sustained-release prostate cancer treatment market. Compared to Lupron, Loopone reduces the drug particle size and injection gauge. It is evaluated to have secured competitiveness after launch by improving quality and dosing convenience. LG Chem has secured the domestic distribution rights for Loopone in Korea. Overseas sales are reportedly being discussed with multiple companies. The global Lupron market size reaches approximately 2.7 trillion KRW annually.
The commercialization of Loopone is also expected to have a positive impact on Peptron’s technology exports related to 1- to 2-month sustained-release diabetes and obesity treatments. There are also expectations that results will be announced in the first half of this year. Peptron’s diabetes and obesity treatments, ‘PT403’ and ‘PT404,’ similarly apply Peptron’s sustained drug delivery technology, SmartDepot. Expectations are growing that Peptron will succeed in technology exports worth over 1 trillion KRW with PT403 and PT404. According to pharmaceutical market research firm Evaluate Pharma, the global obesity treatment market is projected to grow from 2.8 billion USD in 2022 to 16.7 billion USD in 2028. Including diabetes treatments, the related market is expected to exceed 100 trillion KRW by 2028.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
